Clinical trial · Observational
Memory Phenotype and PD-1 Inhibition Response in Oral Cancer
The Role of the Central Memory Phenotype in Predicting Response to PD-1 Inhibition in Pre-clinical Models of Oral Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual progress per internal scientific review committee
Summary
Brief summary (as posted)
The purpose of this research study is collect tissue and blood samples from patients who are having surgery and use those samples in lab studies to see if there are any markers in blood and tissue that can help predict how cancer will react to different treatment. Participants in this study will have a blood sample and tissue samples collected for research. The blood and tissue collected will be tested in the laboratory. The tissue collected will be left over tissue from the standard of care surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of the Head and Neck | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood collection | Other | — | UNRESOLVED |
| Tissue collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Received Nivolumab
- interventionNames
- Other: Blood collection
- Other: Tissue collection
- label
- Nivolumab Naive
- interventionNames
- Other: Blood collection
- Other: Tissue collection
Primary outcomes (1)
- measure
- Count of PDX models that are developed from patient samples
- timeFrame
- 6 months
- description
- It is anticipated that there will be 12 successful PDX models developed as part of this study.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Newly diagnosed histologically proven locoregional oral squamous cell carcinoma (OSCC) without evidence of distant metastases. OSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar trigone and buccal mucosa OR Recurrent or persistent histologically proven locoregional OSCC that was initially treated with surgery alone. * must be eligible for surgical resection * greater than 18 years of age Exclusion Criteria: * prior immunotherapy or treatment with another anti PD-1 agent besides nivolumab * prior chemotherapy including cetuximab or radiation therapy * concomitant malignancies except cutaneous squamous cell carcinoma or basal cell carcinoma * unresectable primary tumor or regional disease or distant metastases
References
Publications (0)
Data not yet available